Medical information Clinical review pending

Cytogenetics

Comprehensive Tumor Panel SNVs Small Indels Fusions TMB MSI 526 Genes

A comprehensive genetic test analyzing 526 genes for SNVs, small indels, fusions, TMB, and MSI in tumor tissue. This test helps guide personalized cancer treatment decisions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides. Confirm specific requirements with the laboratory before booking.
Results: Confirm with the laboratory before booking.
Preparation: No specific patient preparation is required. Ensure the tumor tissue sample is properly collected and preserved according to laboratory guidelines. Consult your doctor for details.

Test priceKSh 158,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Comprehensive Tumor Panel SNVs Small Indels Fusions TMB MSI 526 Genes test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Diagnosis of solid tumors.
✓Guiding treatment selection for cancer patients.
✓Identifying potential targets for therapy.
✓Assessing prognosis and risk of recurrence.
✓Evaluating eligibility for clinical trials.
✓Monitoring treatment response.

In plain language

What this test helps you understand

This test provides detailed genetic information about a tumor, aiding oncologists in selecting targeted therapies, understanding prognosis, and identifying potential clinical trial options. It helps personalize cancer treatment based on the specific molecular characteristics of the tumor.

The Comprehensive Tumor Panel SNVs Small Indels Fusions TMB MSI 526 Genes test is an advanced diagnostic tool used to analyze the genetic makeup of tumors. It examines a wide range of genetic alterations, including single nucleotide variants (SNVs), small insertions and deletions (indels), and gene fusions across 526 genes. This test also assesses tumor mutational burden (TMB) and microsatellite instability (MSI), which are important indicators for predicting response to certain cancer therapies. Understanding these genetic details is crucial for tailoring effective and personalized cancer treatment plans. This test is designed to provide oncologists with comprehensive information to guide treatment decisions, potentially improving patient outcomes. Discuss the relevance of this test with your doctor.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo specific patient preparation is required. Ensure the tumor tissue sample is properly collected and preserved according to laboratory guidelines. Consult your doctor for details.

SampleFormalin-fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides. Confirm specific requirements with the laboratory before booking.

MethodologyNext-Generation Sequencing (NGS) is typically used to analyze the DNA extracted from the tumor sample. This allows for the simultaneous detection of multiple genetic alterations.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test analyzes a specific set of genes and alterations. It may not detect all possible genetic changes in a tumor. Results should be interpreted in the context of the patient's clinical history and other diagnostic findings. Confirm with the laboratory before booking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

A tumor panel test analyzes the genetic material (DNA) from a tumor sample to identify specific mutations or alterations that may be driving the cancer's growth.

Understanding the genetic makeup of a tumor helps doctors choose the most effective treatments, predict how the cancer might respond to therapy, and potentially identify clinical trials.

Tumor Mutational Burden (TMB) measures the number of mutations in a tumor's DNA, while Microsatellite Instability (MSI) assesses changes in short DNA segments. Both can help predict response to certain immunotherapies.

Your oncologist will interpret the results in the context of your specific cancer type and medical history to guide treatment decisions.

Insurance coverage varies. Please check with your insurance provider regarding coverage for this specific test.

You can book this test by contacting our laboratory directly at +254711564616 or through your referring physician.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp